Form 4 for ALLO Allogene Therapeutics, Inc.
Accepted 2023-03-24 00:00:00 ET · period of report 2023-03-22 · accession 0001593968-23-000523 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-03-24 | 2023-03-22 | ALLO | Belldegrun Arie | Dir | A - Grant | $0.00 | +1.28M | 1.65M | +345% | $0 |
| D | 2023-03-24 | 2023-03-22 | ALLO | Belldegrun Arie | Dir | A - Grant | $0.00 | +994.8K | 994.8K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-03-22 | A | A | 1,282,976 | $0.00 | 1,654,886 | D | — | — | (F1) Includes 986,905 of performance RSUs which shall vest as follows: (1) 50% shall vest if the 30-day weighted average stock price is equal to or greater than $18 and (2) 50% shall vest upon the first regulatory approval of a product candidate. Notwithstanding the foregoing (1) any portion that vests upon the stock price threshold shall no longer vest and be terminated after three years from the grant date if such threshold has not been met in such three-year period, and (2) any portion that vests upon product candidate approval shall no longer vest and be terminated after five years from the grant date if such approval has not occurred in such five-year period. |
| 2 | Derivative | Stock Option (Right to Buy) | 2023-03-22 | A | A | 994,800 | $0.00 | 994,800 | D | $5.04 · — to 2033-03-22 | 994,800 Common Stock | (F5) 25% of the shares subject to the stock option shall vest on March 13, 2024, and the remaining shares shall vest in 36 equal monthly installments thereafter. |